65,437 trials
Coronary Artery Disease
Primary: Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE) — 89.6 Percent probability of Freedom from MACE
HIV-1 Infection
Primary: Cumulative Probability of Virologic Failure by Week 48 — 10.3; 12.4 cumulative probability per 100 persons
Aging
Primary: Mixed Muscle Fractional Synthesis Rate (FSR) — 0.061; 0.070; 0.066; 0.070 Fractional Synthesis Rate (pecent/hour)
Hypertension and Chronic Heart Failure
Primary: Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period — 28; 0; 0; 0 % of subject…
Peripheral Arterial Disease · Type II Diabetes Mellitus
Primary: Change in Exercise Capacity - Maximal Oxygen Capacity (VO2peak) — 0.85; -0.15 ml/kg/min
Psoriasis, Plaque-type Psoriasis
Primary: Percentage of Participants Achieving Skin Histology Response After Secukinumab Treatment From Baseline to Week 12 — 56.5; 0.0 percentage of participants — p=<0.001
Uveitis
Primary: Number of Participants Achieving Treatment Success — 24; 15 participants — p=0.09
Physical Activity
Primary: Mean Daily Step Count — -616; 408 steps per day
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response. — 41 percentage of evaluable patients
Severe Hepatic Impairment
Primary: AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine — 166.955; 188.663 ng*hr/mL
Adult T-Cell Leukemia-Lymphoma
Primary: Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee…
Diabetic Autonomic Neuropathy
Primary: Global [11C]HED Retention Index (RI) — 0.081; 0.073; 0.070; 0.074 Retention index — p=0.32
Critically Ill
Primary: MICU Length of Stay — 52.8; 52.6 hours
Hypertension
Primary: Change in Blood Pressure After Intrathecal Injection of Clonidine. — 79; 37 mm Hg